NCT03960840 2026-01-09Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLNovartisPhase 1/2 Active not recruiting217 enrolled
NCT03267186 2023-08-01Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell TransplantStanford UniversityPhase 2 Completed8 enrolled 13 charts
NCT02129062 2017-01-16Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 2 Terminated3 enrolled 4 charts
NCT02109224 2015-08-20Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNational Cancer Institute (NCI)Phase 1 Terminated72 enrolled